Servier to acquire Edgewise muscular dystrophy business in $2.65 billion deal

The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments

CORONA Remedies receives EU-GMP certification for hormone facility

Accreditations for Bhayla manufacturing site strengthen the company’s global quality credentials and support expansion of its hormone portfolio into regulated international markets

Marksans Pharma to acquire Netherlands-based QliniQ

Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets

AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications

Takeda promotes Garima Srivastava as VP HR, Global Head of Talent Acquisition for Commercial

Seasoned HR leader brings over 15 years of experience in global talent strategy, organizational transformation, and workforce planning

Samsung Bioepis launches Aflibercept biosimilar OPUVIZ across Europe

The aflibercept biosimilar, referencing Eylea, becomes the company’s fifth directly commercialized biosimilar in Europe, expanding access to ophthalmology treatments

Pfizer and Innovent Biologics strike $10 billion cancer drug deal

This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants

Clariant bags FDA nod for bio-based PVC additives

Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes

Glenmark posts strong FY26 results with 27.5% revenue jump

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis